Skip to content

Finding ways to improve cervical cancer screening programs for women (SHE-CAN study).

Developing a scalable, woman-centred model for cervical cancer screening in vulnerable women in India, the SHE-CAN study (Self-collected HPV Evaluation for the Prevention of Cervical CANcer). - SHE-CAN

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/04/042327
Enrollment
6600
Registered
2022-04-29
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: HPV self collection at home: Eligible women aged 30-49 years will be given education and HPV kits to self collect vaginal samples which will be tested for HPV. Those who are screen posi

Sponsors

Australian Centre for the Prevention of Cervical Cancer ACPCC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All women in the selected clusters, aged 30-49 years, married, with no previous history of cervical cancer, with an intact uterus

Exclusion criteria

Exclusion criteria: Clusters where a recent HPV based screening trial has been done History of cervical cancer/hysterectomy Pregnancy Women with abnormal inter-menstrual or post-menopausal bleeding Menstruation or within 12 weeks of delivery/abortion.

Design outcomes

Primary

MeasureTime frame
percent well managed (Completed a valid screening test (sample processed successfully to positive or negative result, including recollection of invalid samples) AND i) for HPV negative women, woman advised of negative result or ii) for HPV positive women, completed assessment and, if needed, treatment]Timepoint: 12 months (end of trial)

Secondary

MeasureTime frame
Representativeness of screened participants out of eligible womenTimepoint: 12 months (end of trial);Acceptability of HPV self samplingTimepoint: 12 months (end of trial);Cost effectiveness in terms of incremental costs per QALY gained, cost per case screened and treatedTimepoint: 12 months (end of trial)

Countries

India

Contacts

Public ContactDr Anu Mary Oommen

Christian Medical College Vellore

anuoommen@cmcvellore.ac.in9486368796

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026